Gilteritinib is a targeted therapy used to treat acute myeloid leukemia (AML) with FLT3 mutations. It belongs to the class of protein kinase inhibitors, working by blocking the activity of the FLT3 enzyme, which is crucial for the growth and survival of certain cancer cells. Gilteritinib is often prescribed for patients with relapsed or refractory AML. Common side effects may include fatigue, fever, and nausea. In summary, Gilteritinib is an effective treatment option for specific AML patients.
Gilteritinib inhibits the FLT3 receptor tyrosine kinase, leading to reduced proliferation and survival of FLT3-mutated leukemia cells.
No published brands for this salt yet.